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Background: To explore the current landscape of seasonal influenza vaccination across China, and
estimate the budget of implementing a national ‘‘free-at-the-point-of-care” vaccination program for
priority populations recommended by the World Health Organization.
Methods: In 2014 and 2016, we conducted a survey across provincial Centers for Disease Control and
Prevention to collect information on regional reimbursement policies for influenza vaccination, estimated
the national uptake using distributed doses of influenza vaccines, and evaluated the budget using popu-
lation size and vaccine cost obtained from official websites and literatures.
Results: Regular reimbursement policies for influenza vaccination are available in 61 mutually exclusive
regions, comprising 8 provinces, 45 prefectures, and 8 counties, which were reimbursed by the local
Government Financial Department or Basic Social Medical Insurance (BSMI). Finance-reimbursed vacci-
nation was offered mainly for the elderly, and school children for free in Beijing, Dongli district in
Tianjin, Karamay, Shenzhen and Xinxiang cities. BSMI-reimbursement policies were limited to specific
medical insurance beneficiaries with distinct differences in the reimbursement fractions. The average
national vaccination coverage was just 1.5–2.2% between 2004 and 2014. A free national vaccination pro-
gram for priority populations (n = 416 million), would cost government US$ 757 million (95% CI 726–
789) annually (uptake rate = 20%).
Conclusions: An increasing number of regional governments have begun to pay, partially or fully, for
influenza vaccination for selected groups. However, this small-scale policy approach has failed to increase
national uptake. A free, nationwide vaccination program would require a substantial annual investment.
A cost-effectiveness analysis is needed to identify the most efficient methods to improve coverage.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Annual seasonal influenza epidemics represent a major disease
burden globally, with 3–5 million cases of severe illness that resultin over a quarter of a million deaths every year [1]. Influenza vac-
cination is the most effective way to prevent disease, and the
World Health Organization (WHO) recommends annual seasonal
influenza vaccination for pregnant women, children aged six to
59 months, the elderly, persons with specific chronic medical con-
ditions, and health-care workers (hereafter called the ‘‘priority
populations”) [2]. As of 2014, over 100 countries worldwide
already have seasonal influenza vaccination policies that recom-
mend vaccination of at least one of the risk groups [3]. Over 40%
of countries list seasonal influenza vaccination on their National
Immunization Schedule, including most countries across North
J. Yang et al. / Vaccine 34 (2016) 5724–5735 5725and South America, Europe, and some countries in African, South-
East Asia, and the West Pacific Region [4–8].
Despite seasonal influenzabeingassociatedwithbetween67,000
and 430,000 annual excess respiratory and circulatory deaths on
average for five pre-pandemic influenza seasons 2004–2005
through 2008–2009 [9], influenza vaccination is not included on
the National Immunization Program (NIP) in China. Therefore, there
are no national guidelines for alleviating the cost burden on individ-
uals who wish to receive the vaccine, which may contribute to low
vaccine uptake of 19% for the entire population in China and 4.3%
for the urban residents aged above 60 years old in 9 cities, recorded
during the 2008–2009 and 2011–2012 influenza season, respec-
tively [10,11]. Thus, vaccineuptake inChina falls substantiallybelow
the World Health Assembly (WHA) target of 75% in the elderly by
2010 [12], and also below that of other upper-middle income coun-
tries such as Brazil where coverage is over 70% in the elderly [6].
In countries where vaccination costs are subsidized by the
respective governments, there is higher national vaccine uptake
[13,14]. To our knowledge, only a handful of large cities in China
currently provide reimbursement for influenza vaccination. For
example, since 2007, Beijing has provided free seasonal influenza
vaccination to the elderly and school children, and since 2004,
Xi’an city in Shaanxi province has provided free vaccination to
those covered by Medicare insurance [10]. Unlike NIP vaccines
funded by the central government, there is a diverse patchwork
of reimbursement policies that exist at the provincial, prefecture
and county levels for influenza vaccination.
WHO has called upon China to include more vaccines in NIP,
following a recent vaccine scandal with improperly refrigerated
of transported vaccines sold nationwide [15]. To inform a future
national government-funded free seasonal influenza vaccination
program for China that harnesses the advantages of regionally
administrated schemes and provides a sustainable public health
strategy, we conducted a survey to explore the current landscape
of influenza vaccination, including reimbursement policies, eligi-
ble subgroup sizes, and influenza vaccine uptake across China.
We then estimate the budget needed to implement a nationwide
‘‘free-at-the-point-of-care” vaccination program by conducting a
budget impact analysis parameterized with province-level data
for the size of the subgroups—delineated by age and risk
group—eligible to receive an influenza vaccine.2. Methods
2.1. Landscape of influenza vaccination across China
2.1.1. Regional reimbursement policies for influenza vaccination
Between August and November, 2014, we conducted a survey
across all 31 provincial Centers for Disease Control and Prevention
(CDCs) to collect information on provincial-level reimbursement
policies for influenza vaccination (and at the prefecture- and
county-level if applicable), and performed a web search of below
official websites to validate the responses: (1) all 31 provincial-
level and 333 prefecture-level governments, (2) the Bureau of
Human Resources and Social Security, (3) the Commission of
Health and Family Planning, and (4) the provincial CDCs (see ques-
tionnaire in supplementary 1). Nearly two years have passed since
our initial survey mentioned above. To check whether there were
major new vaccination policies implemented across China
between December 2014 and September 2016, we re-searched
all the aforementioned official websites.2.1.2. Eligible subgroup size of regional reimbursement policies
For the regions where reimbursement policies are available
for influenza vaccination, the eligible population mainly includesubgroups at a certain age, school children, health-care workers,
and/or insured persons of Basic Social Medical Insurance (BSMI)
(including New Rural Cooperative Medical Insurance for Rural
Residents (NRCMI), Basic Social Medical Insurance for Urban
Employees (BSMIUE), and Basic Social Medical Insurance for
Urban Residents (BSMIUR)) (see details for the introduction to
BSMI in supplementary 2). To estimate the size of subgroups eli-
gible for reimbursement, local age-specific population data and
the number of school children were obtained from National
Bureau of Statistics [16], the number of health-care workers
was gained from local Health Statistics Yearbook, and the num-
ber of insured persons was collected from the four official web-
sites described above.
2.1.3. Influenza vaccine coverage
We estimated the national yearly influenza vaccine uptake rate
in China using the annual number of doses of seasonal influenza
vaccine released between 2004 and 2014 from the website of the
National Institutes for Food and Drug Control. In China, all unsold
influenza vaccines are returned to the manufacturers at the end
of each season for disposal. We used a 14–31% return rate [10],
and 1–10% vaccine wastage rate, resulting from physical damage,
expiration, losses in transit, consistent with the wastage of single
dose vaccines in 7 GAVI-eligible countries [17–19].
2.2. Budget impact analysis under a free national vaccination program
for priority populations
2.2.1. The size of priority populations
We used 2013 National Bureau of Statistics age-specific popula-
tion data to estimate the size of priority populations stratified by
provinces [16]. According to the latest guidelines of influenza vac-
cination issued by China CDC [20], the priority populations for
influenza vaccination in China includes those recommended by
WHO [2], and family members and caregivers of infants younger
than 6 months. For global comparisons, we used the WHO defini-
tion of priority populations. The detailed calculation of priority
populations size was provided below.
We estimated the number of pregnant women as the sum of
number of live births, still births, fetus deaths and abortions. The
number of live births was obtained from China Health Statistical
Yearbook (CHSY) in 2013 [21]. The number of still birth and fetus
deaths were estimated as the product of the number of perinatal
deaths [21] and the fraction of those deaths which are still births
and fetus deaths (68.59%) [22]. We estimated the number of abor-
tions by dividing the number of induced abortions [21] by the
proportion of induced abortions (88.54%) [23]. The number of
health-care workers was obtained from the CHSY in 2013 [21].
To minimize the overlap among persons with specific chronic med-
ical conditions, children aged six to 59 months and the elderly, we
estimated the number of persons with chronic illness only in those
aged 5–59 years, multiplying the age-specific population size by
the age-specific prevalence of chronic conditions.
We performed a literature review to obtain the prevalence of
underlying medical conditions in China which are related to
increased risk of hospitalization and mortality if infected with
influenza. We searched articles published in PubMed, Wanfang
and CNKI during 2000–2014, with terms including above specific
disease as ‘‘asthma” and ‘‘China”, and ‘‘prevalence”/‘‘disease bu
rden”/‘‘epidemic”/‘‘epidemiological”/‘‘epidemiology”. All identi-
fied papers were reviewed, and the most recent national repre-
sentative studies were included [21–39]. We summed the
prevalence of each chronic disease to get the prevalence by dis-
eases (e.g., a person with three chronic diseases was counted
three times) (Table 1). To get the prevalence by cases (e.g., a per-
son with more than one chronic diseases was counted only one
5726 J. Yang et al. / Vaccine 34 (2016) 5724–5735time), we multiplied prevalence by diseases with a ratio of
prevalence by cases to prevalence by diseases, which was
obtained from the 4th National Health Service Survey of China
in 2008 [35] (Table 1). We specifically estimated the size of pri-
ority populations in regions with reimbursement policies as well,
using the same methods for estimating that stratified by pro-
vinces described above.2.2.2. Budget impact analysis
We evaluated the budget necessary for a free-at-the-point-of-
care trivalent inactivated influenza vaccine (TIV) program for pri-
ority populations. TIV is administered in doses of 025 ml for
infants 6–35 months, and 050 ml for the rest of the population
[20]. Considering the very low uptake rate [10] of influenza vacci-
nes in China, we assumed conservatively that children aged
6 months to 8 years will have never received an influenza vaccine
and therefore would require two doses in the first year of the pro-
gram. There is significant uncertainty in the coverage that may be
achieved in a potential national free vaccination program. The
experience of Beijing showed that the uptake in the elderly
increased substantially (1.69% in 1999 vs. 43% in 2010) [40,41]
after free influenza vaccination was offered in 2007. It is likely that
the uptake in other less dense and development provinces would
not increase as quickly as Beijing, the capital of China where resi-
dents likely have greater access to health care facilities and there
are likely disproportionately more educated persons. We esti-
mated the budget with a conservative base-case uptake rate of
20% [42] and a conservative vaccine wastage rate of 10% [17].
We also conducted a sensitivity analysis to estimate the impact
of uncertainty of uptake rate (10%, 40% and 75%), and wastage rate
(lower limit = 1%) [17] on the total budget. Moreover, we used age-
specific vaccine uptake as well as risk-group-specific vaccine
uptake (40% for children aged 6–59 months, 20% for the elderly,
persons aged 5–59 years with underlying chronic illness and
health-care workers, and 10% for pregnant women, according to
the difference in uptake rates which was observed in nine cities
in China [11]) to estimate the national budget.
Influenza vaccine types that are used in specific regions are
determined and centralized purchased by local provincial, prefec-
ture or even district level CDCs, and then distributed to lower level
CDCs and/or Points of Vaccination [43]. Procurement of influenza
vaccine is conducted by negotiated between government and man-
ufactures. To obtain the influenza vaccine cost in China, we
searched the official websites of provincial and prefecture-level
authorities, which included the Price Bureau, Development and
Reform Commission, Health Bureau, CDCs and government portal
website. When considering the overall vaccination program costs
(including training, advocacy, etc.) (US$1.27 per dose for the
provincial Expanded Program on Immunization in Guizhou pro-
vince) [44], and assuming the existing cold-chain infrastructure
could be used for a national seasonal influenza vaccination pro-
gram, the influenza vaccination cost per capita during 2011–
2013 was separately US$4.87 per dose (95%CI 4.62–5.11) for
0.25 ml formulation and US$7.17 per dose (95%CI 6.89–7.46) for
0.50 ml formulation. All costs were updated to 2015 CNY using
the consumer price index [45] and expressed in US dollars using
the median 2015 exchange rate of 1 US$ = 62 CNY [46].3. Results
3.1. Landscape of influenza vaccination across China
3.1.1. Regional reimbursement policies for influenza vaccination
Regular reimbursement policies for influenza vaccination are
available in 61 mutually exclusive regions across China, compris-ing 8 out of 31 provinces, 45 out of other 253 prefectures and 8
out of remaining 1782 counties. Influenza vaccination in these
regions was reimbursed fully or partially by the local Government
Financial Department (hereafter called Finance-reimbursed vacci-
nation), or BSMI. According to the BSMI types and reimbursement
modes, the BSMI-reimbursed policy was further broken down into
3 subgroups: (1) NRCMI-reimbursed vaccination; (2) BSMI-
proportional-reimbursed vaccination, which was proportionally
reimbursed by BSMIUE and/or BSMIUR; (3) BSMIUE-MSA-
reimbursed vaccination which was reimbursed using an individual
card of Medical Savings Account (MSA) of BSMIUE.
Annual Finance-reimbursed vaccination is offered free of charge
in Beijing, Dongli district in Tianjin, Karamay in Xinjiang province,
Shenzhen in Guangdong province and Xinxiang in Henan province.
NRCMI-reimbursed vaccination is available in seven counties and
one prefecture, BSMI-proportional-reimbursed vaccination avail-
able in five prefectures, and BSMIUE-MSA-reimbursed vaccination
available in seven provinces and 38 prefectures (there are two
types of policies available in Xinxiang and Shenzhen, respectively).
There were also several one-off large-scale free influenza vaccina-
tion programs in a few cities (e.g., Chengdu of Sichuan province,
and Jinzhou of Liaoning province), mainly as a result of natural dis-
asters (e.g., 2008 earthquake in Sichuan province, and 2013 flood in
Liaoning province). (Fig. 1 and Table 2, and more details shown in
supplementary Table 1s.) It’s noted that BSMI-proportional-
reimbursed vaccination for insured persons in Xi’an of Shaanxi pro-
vince was only implemented between 2004 and 2006; in 2015,
BSMI resumed reimbursement for influenza vaccination, i.e., urban
employees can use the surplus fund of individual BSMIUE MSA
card to pay for influenza vaccination for their own and their
families.
Significant differences were also observed for the reimburse-
ment fractions among these four reimbursement policies. For
example, in BSMI-proportional-reimbursed vaccination regions,
the reimbursement fraction ranged from 30% (Zhaoqing in Guang-
dong province) to 100% (e.g., Kaifeng in Henan province). Impor-
tantly, the reimbursement fraction of BSMIUE-MSA-paid
vaccination relies on the availability of surplus funds in the indi-
vidual BSMIUE-MSA accounts (Table 2).3.1.2. Eligible subgroup size of regional reimbursement policies
The eligibility criteria for reimbursement varied significantly.
Annual Finance-reimbursed vaccination was mainly offered for
the elderly, school children and health-care workers. BSMI-
reimbursement policies were limited to specific medical insurance
beneficiaries. Considerable differences were observed for the num-
ber of eligible subgroups: Finance-reimbursed vaccination covered
57 million persons, NRCMI-reimbursed vaccination covered
72 million, BSMI-proportional-reimbursed vaccination covered
58 million, and BSMIUE-MSA-reimbursed vaccination covered
102.8 million. The NRCMI-reimbursed vaccination covered over
70% of local population aged 6 months and over. The coverage of
most of other reimbursed vaccination was less than 30% (Fig. 2).
In regions with regular reimbursement policies, priority popula-
tions represented an average of 31% of the local population aged
6 months and above. In 59% (36/61, excluding Kaifeng and Inner
Mongolia where the size of the eligible population was unavail-
able) of regions, the size of the eligible population was less than
that of priority populations (Fig. 2). In 86% (n = 50) of the 58
regions where influenza vaccination was reimbursed by BSMI,
the policy focused on the insured persons irrespective of member-
ship in a priority risk group (Table 2). For example, there were
463,000 people in the priority populations in Changji of Xinjiang
province, while only 238,300 urban employees registered in BSI-
MUE were covered by BSMIUE-MSA-reimbursed vaccination.
Table 1
The prevalence of underlying medical conditions related to increased risk of hospitalization and mortality if infected with influenza in China*.
0-years 5-years 15-years 25-years 35-years 45-years 55-years 60+ years
Chronic obstructive pulmonary disease (COPD) [24,25] / / 0.07% 0.45% 1.94% 3.52% 8.05% 15.49%
Asthma [26,27] 2.78% 2.05% 0.37% 0.43% 0.59% 1.07% 1.48% 1.83%
Chronic cardiac disease
Coronary heart disease [28] / / / / 0.17% 0.72% 1.30% 1.45%
Chronic heart failure [29] / / / / 0.40% 1.00% 1.30% 1.30%
Congenital heart disease [30] / 0.57% / / / / / /
Chronic liver disease
Primary binary cirrhosis [31] / / 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
Alcoholic liver hepatitis and cirrhosis [32] / / / 1.16% 1.16% 1.16% 1.16% 1.16%
Chronic hepatitis B [33] / 0.33% 1.17% 1.80% 1.75% 1.46% 1.14% 0.98%
Chronic renal failure [34] / / 0.03% 0.03% 0.03% 0.03% 0.03% 0.03%
Chronic haematological disorder [35] 0.06% 0.05% 0.06% 0.11% 0.23% 0.34% 0.34% 0.29%
Chronic neurological disease [35] 0.07% 0.10% 0.21% 0.20% 0.40% 0.48% 0.74% 0.98%
Diabetes [36,37] / 0.12% 3.98% 5.66% 6.57% 14.17% 17.60% 22.86%
Tuberculosis [38,39] 0.09% 0.09% 0.25% 0.23% 0.29% 0.42% 0.58% 1.11%
Prevalence by diseases (sum of prevalence of above diseases) 3.01% 3.30% 6.14% 10.12% 13.58% 24.41% 33.77% 47.53%
Ratio of prevalence by cases to prevalence by diseases [35] 1.00 1.00 1.00 0.92 0.87 0.82 0.78 0.73
Prevalence by case 3.01% 3.30% 6.14% 9.32% 11.80% 20.09% 26.46% 34.48%
/data were unavailable and assumed to be zero.
* The prevalence of other chronic illness (e.g., immunodeficiencies related to use of immunosuppressive drugs, morbid obesity with a BMI > 40 kg/m2) were not available, and
hence not included in the analysis.
Fig. 1. Map of reimbursement policy for influenza vaccination in China till 2016.
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Between 2004 and 2010, influenza vaccine supply increased
by 235% from 175 to 588 million doses. This translates to a rise
from 136 to 441 doses/1000 people, and on average 722% of
doses were manufactured in China. The sharp increases in dose
distribution in the 2010–2011 influenza season were likely
because of the greater social attention and public awareness sur-rounding the 2009 H1N1 pandemic. However, the influence of
the pandemic on increased distribution did not last long. After
2010 the number of doses distributed nationally decreased by
35%, to near 2008 levels, with 282 doses/1000 people in 2013.
This drop was despite 45 of 61 regions beginning reimbursement
policies in 2010 or later (Fig. 3). Distributed influenza vaccines
were only sufficient for 13–36% of the total population aged
Table 2
The long-term reimbursement policy for seasonal influenza vaccination in China till 2016.
Province City/county Eligible population Reimbursement fraction of influenza vaccination by
governmenta
I. Finance-reimbursed vaccinationb
Beijing / School children and residents aged 60 years and
over
100%
Tianjin Dongli district Residents aged 65 years and over 100%
Xinjiang Karamay Residents aged 60 years and over, 3–7 years
children, school children and teachers, medical
workers, polices
100%
Guangdong Shenzhen Insured residents aged 60 years old and over 100%
Henan Xinxiang Residents aged 65 years and over 100%
II. NRCMI-reimbursed vaccinationb
Gansu (1) Gaotai⁄, Lingtai⁄
(2) Min⁄
(1) Insured persons
(2) Insured persons aged 60 years and over
(1) 80%, 100%
(2) 100%
Jiangsu Huaiyin⁄ Insured persons 30%
Shandong (1) Liaocheng, Wudi⁄ and
Zouping⁄
(2) Wenshang⁄
(1) Insured persons
(2) Insured persons aged 60 years and over
(1) US$ 4.84, 100% and 100%, separately
(2) 100%
III. BSMI-proportional-reimbursed vaccinationb
Guangdong Zhaoqing Insured persons 30% by BSMIUE and BSMIUR
Henan Jiaozuo, Kaifeng and Pingdingshan Insured persons Separately 40–100%, 100%, and 50–100%
Xinjiang Changji Insured persons 100% by BSMIUE
IV. BSMIUE-MSA–reimbursed vaccinationb
Anhui, Chongqing,
Fujian, Hubei,
Guangxi
/ Insured persons Using the surplus fund of BSMIUE MSA
Inner Mongolia / Insured provincial-level employees Using the surplus fund of BSMIUE MSA
Yunnan / Insured persons and their families Using the surplus fund of BSMIUE MSA
Gansu Zhangye Insured persons and their families Using the surplus fund of BSMIUE MSA
Guangdong (1) Chaozhou, Dongguan,
Foshan, Guangzhou,
Huizhou, Zhuhai, Zhanjiang
(2) Shenzhen
(1) Insured persons and their families
(2) Insured persons
(1) Using the surplus fund of BSMIUE MSA
(2) Using the surplus fund of BSMIUE MSA only when
the surplus fund surpass average monthly income
in the last year
Guizhou Bijie Insured persons Using the surplus fund of BSMIUE MSA
Hebei (1) Cangzhou
(2) Hengshui
(1) Insured persons
(2) Insured persons and their families
Using the surplus fund of BSMIUE MSA
Heilongjiang (1) Haerbin
(2) Jiamusi
(1) Insured persons
(2) Insured persons and their families
Using the surplus fund of BSMIUE MSA
Henan Sanmenxia, Xinxiang Insured persons Using the surplus fund of BSMIUE MSA
Hunan Yueyang Insured persons Using the surplus fund of BSMIUE MSA
Jiangsu (1) Lianyungang, Suqian,
Suzhou, Wuxi, Yancheng,
Yangzhou
(2) Taizhou
(1) Insured persons
(2) Insured persons and their families
Using the surplus fund of BSMIUE MSA
Jilin Changchun Insured persons Using the surplus fund of BSMIUE MSA
Liaoning Dalian, Jinzhou, Panjin, Shenyang Insured persons Using the surplus fund of BSMIUE MSA
Shaanxi Xi’an Insured persons and their families Using the surplus fund of BSMIUE MSA
Sichuan (1) Ya’an
(2) Mianyang, Deyang
(1) Insured persons
(2) Insured persons and their families
Using the surplus fund of BSMIUE MSA
Zhejiang (1) Hangzhou, Ningbo, Shaoxing
(2) Huzhou, Taizhou
(1) Insured persons
(2) Insured persons and their families
Using the surplus fund of BSMIUE MSA
/Province.
⁄County.
a The cost of influenza vaccination is co-paid by individuals and government. The cost that individuals should pay is total cost of influenza vaccination per capita minus the
fraction which is reimbursed by government. 100% reimbursement refers to that the vaccinees can get free of charge influenza vaccination at point of care. NRCMI: new rural
cooperative medical insurance for rural residents; BSMIUE: basic social medical insurance for urban employees, including Social Pooling Account for inpatient care and
individual Medical Savings Account for outpatient care (it represents Social Pooling Account if not specified in this paper); BSMIUR: basic social medical insurance for urban
residents; BSMIUE MSA: individual Medical Savings Account of BSMIUE.
b Finance-reimbursed vaccination: the cost of influenza vaccination is fully covered by local Financial Department. NRCMI-reimbursed vaccination: the cost of influenza
vaccination is proportionally borne by NRCMI. BSMI-proportional-reimbursed vaccination: the cost of influenza vaccination is proportionally paid by BSMIUE and/or BSMIUR.
BSMIUE-MSA–reimbursed vaccination: the cost of influenza vaccination is borne using the surplus fund of BSMIUE individual accounts.
5728 J. Yang et al. / Vaccine 34 (2016) 5724–57356 months and over, and for between 45 and 115% of the priority
populations in China throughout the period. Assuming a manu-
facture return rate of 31% [10] and a wastage rate of 10% [17],
the distributed influenza vaccines was on average sufficient to
cover just 15% of the total population between 2004 and 2014
(range: 08% in 2004 to 22% in 2010). Using a manufacture
return rate of 14% [10] and a wastage rate of 1% [17], the average
uptake rate would be 20% (range: 11% in 2004 to 31% in 2010).3.2. Budget impact analysis under a free national vaccination program
for priority populations
3.2.1. The size of priority population
The population aged six months and over was 135 billion in
2013, of which 31.6% (426 million) would be included in the prior-
ity populations for influenza vaccination. Of these, 45% (193 mil-
lion) were the elderly aged 60 years and above, 30% (129 million)
Fig. 2. Proportion of priority populations and eligible subgroup for reimbursed influenza vaccination stratified by policies and by regions. A: The cost of influenza vaccination
is fully covered by local Financial Department, called Finance-reimbursed vaccination; B: Proportionately reimbursed by New Rural Cooperative Medical Insurance for rural
residents, called NRCMI-reimbursed vaccination; C: Proportionately reimbursed by Basic Social Medical Insurance for urban employees and/or residents, called BSMI-
proportional-reimbursed vaccination; D: Paid by surplus fund of Basic Social Medical Insurance for urban employees, called BSMIUE-MSA-reimbursed vaccination. ⁄county;
⁄⁄province; other regions are prefectures. #Taizhou in Jiangsu province; ##Taizhou in Zhejiang province. Note: (1) For six regions (Hubei, Jiamusi, Jilin, Lingtai, Zhangye, and
Yancheng) where the reimbursement policy started in 2014, we used the information in 2013 (regarding the number and percentage of priority population and policy covered
population) as a proxy due to data availability. (2) In Kaifeng and Inner Mongolia, the proportion of policy covered population was unavailable in 2013. (3) BSMI-proportional-
reimbursed vaccination for insured persons in Xi’an of Shaanxi province was only implemented between 2004 and 2006; in 2015, BSMI resumed reimbursement for influenza
vaccination, i.e., urban employees can use the surplus fund of individual BSMIUE MSA card to pay for influenza vaccination for their own and their families. Here, we only
presented the population of BSMIUE-MSA-reimbursed vaccination policy for Xi’an. (4) We presented here the population of both BSMIUE-MSA–reimbursed vaccination for all
insured persons (started from 2008) (panel D) and finance-reimbursed vaccination specifically for insured elderly (started from 2016) (panel A) in Shenzhen, Guangdong
province.
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(72 million) were children aged 6–59 months, the remaining 8%
included pregnant women (22 million), and health-care workers
(10 million). The size of the priority populations varied across pro-
vinces, ranging from 08 million in Tibet province to 321 million in
Shandong province (Fig. 4A).
3.2.2. Budget impact analysis
Assuming an uptake rate of 20% [42] and a vaccine wastage rate
of 10% [17], a free, government-funded national vaccination pro-
gram for priority populations, would cost the Chinese government
US$ 757 (95% CI 726–789) million annually for vaccine purchaseand vaccination program operations. Included in this figure is US
$ 309 (297–322) million for the elderly, US$ 210 (202–218) million
for persons aged 5–59 years with underlying chronic illness, US$
187 (178–195) million for children aged 6–59 months, US$ 36
(34–37) million for pregnant, and US$ 16 (14–16) million for
health-care workers (Table 3). The budget ranged from US$ 1.56
(1.50–1.63) million in Tibet province to US$ 56.73 (54.38–59.08)
million in Shandong province (Fig. 4B) (see province details in
Table 3). The budget scales proportionally to the vaccine uptake
rate. The national budget would be US$ 379 (363–394) million,
US$ 1.514 (1.452–1.577) billion and US$ 2840 (2722–2957) bil-
lion at an uptake rate of 10%, 40% and 75%, respectively. When
Fig. 3. Numbers and proportion of distributed doses of domestic and imported influenza vaccine in China during 2004–2014.
5730 J. Yang et al. / Vaccine 34 (2016) 5724–5735the wastage rate decreased to 1%, the national budget would be US
$ 344 (330–358) million, US$ 688 (660–717) million, US$ 1.377
(1.320–1.434) billion and US$ 2.582 (2.474–2.688) billion at an
uptake rate of 10%, 20%, 40% and 75%, separately. When age-
specific and risk-group-specific uptake rates were used, the
national budget would be US$ 926 (887–965) million and US$
842 (806–878) billion at a wastage rate of 10% and 1%, respectively.
4. Discussion
The recent vaccine scandal, with massive improperly stored and
distributed category 2 vaccines (refers to those used in private sec-
tor and paid out of pocket) sold in 24 provinces in China [47], trig-
gered heated debates over the regulation and management of
category 2 vaccines. WHO recommends expanding China’s cate-
gory 1 vaccines (refers to those listed in NIP, which are procured
and distributed under official arrangement, and provided free of
charge) list [15]. The State Council of China released an amended
regulation of circulation and management of vaccines. It requires
category 2 vaccines to be distributed in the same way as category
1 vaccines [48]. All these may speed up including more category 2
vaccines in NIP.
The seasonal influenza vaccine is one kind of category 2 vacci-
nes, with coverage far below the 2003 WHA targets of at least
75% of the elderly by 2010 [12]. Eliminating or reducing out-of-
pocket expenses for vaccination is an important enabling factor
for influenza vaccine uptake [13,14,49–52]. To support Chinese
government decision makers considering sustainable implementa-
tion of a national free influenza vaccination program, we evaluated
the current landscape of influenza vaccination across China, and
estimated the budget needed for such a program. We found that
there was wide variation in seasonal influenza vaccination across
provincial-, prefecture- and county-level governmentswith regards
to funding, eligible populations, and reimbursement fractions
across these regions.
Existing reimbursement policies were mainly confined to devel-
oped regions such as Beijing and Karamay, but were also present in
a few less-developed, rural regions. For example, in Min County
since 2011, where Gross Regional Product per capita in 2013
(5755 CNY) [53] is only 14% of the national Gross Domestic Product
per capita average (GDP: 41,908 CNY) [16], local rural residentsaged 60 years old and above who are registered in NRCMI can
get influenza vaccination with no out-of-pocket expenses.
In 86% of regions where influenza vaccination was partly or
fully paid by BSMI, the policy focused on the insured persons irre-
spective of medical high-risk status. This mismatch between prior-
ity populations and populations eligible for reimbursement creates
gaps in coverage and unequal access to vaccination for high risk
groups. A national vaccine program ensuring that Immunization
of the priority populations would have the largest public health
benefit.
Our results suggest that the current reimbursement framework
has failed to stimulate demand for influenza vaccination. Two
possible reasons may account for this: First, the population eligi-
ble for reimbursement (n = 121.5 million) only accounts for about
9% of the national population. Thus, even substantial increases in
uptake among groups eligible for reimbursement will have a very
small impact on overall national uptake rates. Second, the specific
reimbursement policies fail to motivate or incentivize vaccine-
seeking behavior. For example, in BSMIUE-MSA-reimbursed vacci-
nation, the individual MSA is an exclusive account only used by
the insured persons and sometimes their family members. MSA
funds can be used to pay for outpatient and emergency services,
as well as some other category 2 vaccines (e.g., Haemophilus
Influenza B vaccine) [54]. Hence, the insured individuals typically
are less willing to pay for influenza vaccination if they have
higher demand for other outpatient medical services and limited
funds in their MSA. The precise impact of different payment sys-
tems on the uptake of influenza vaccination is important and
merits further investigations.
The 2011 dose distribution per 1000 population in China was
lower than 88 other countries/regions [55]. Despite a general trend
towards increased vaccine supply, the estimated uptake rate has
remained low, on average 15–20% between 2004 and 2014. It
was not possible to estimate the age-specific coverage rate in China
using lot release data. However, even in Beijing, where free influ-
enza vaccination has been provided to the residents aged 60 years
and over since 2007, the coverage rate in the elderly in 2010 was
431% [41], which was far below the WHA target, and that in the
US (667% during the 2014–2015 influenza season) [56], and Brazil
(over 70% since 2001) [6]. WHA stated that better use of vaccines
for seasonal epidemics will help to ensure that manufacturing
Fig. 4. Number of priority populations and budget for influenza vaccination stratified by provinces, China. A: priority population size. B: Budget under a free national
influenza vaccination program for priority population in 2015.
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Table 3
Priority populations size stratified by provinces and budget impact analysis under a free national vaccination program.
Region No. of priority population (thousand) Budget (million, US$) Percent of total budget
in Government Health
Expenditure (‰)a
Percent of total budget
in Gross Domestic/
Regional Product per
capita (‰)a
6–
59 months
Elderly Persons aged
5–59 years
with chronic
illness
Pregnant Health
workers
Total 6–59 months Elderly Persons aged 5–
59 years with
chronic illness
Pregnant Health
workers
Total
Beijing 682 2773 2159 199 263 6076 1.80 (1.72–
1.88)
4.44 (4.26–
4.62)
3.48 (3.34–3.62) 0.32 (0.31–
0.33)
0.42 (0.37–
0.44)
10.46 (10.03–
10.89)
1.767 (1.694–1.839) 0.032 (0.031–0.034)
Tianjin 500 2056 1529 224 107 4415 1.32 (1.26–
1.38)
3.29 (3.16–
3.42)
2.47 (2.37–2.57) 0.36 (0.34–
0.37)
0.17 (0.15–
0.18)
7.61 (7.30–
7.92)
3.153 (3.023–3.282) 0.032 (0.031–0.033)
Hebei 4699 10,528 6943 1179 492 23,841 12.27 (11.71–
12.82)
16.84 (16.17–
17.52)
11.31 (10.86–
11.77)
1.89 (1.81–
1.96)
0.79 (0.69–
0.82)
43.10 (41.30–
44.89)
6.039 (5.787–6.289) 0.092 (0.088–0.096)
Shanxi 1773 4547 3505 451 284 10,560 4.61 (4.40–
4.81)
7.27 (6.98–
7.57)
5.69 (5.46–5.92) 0.72 (0.69–
0.75)
0.45 (0.40–
0.47)
18.75 (17.97–
19.53)
4.918 (4.713–5.121) 0.090 (0.086–0.093)
Inner
Mongolia
1029 3166 2578 275 196 7244 2.70 (2.58–
2.82)
5.07 (4.86–
5.27)
4.18 (4.02–4.35) 0.44 (0.42–
0.46)
0.31 (0.27–
0.33)
12.70 (12.18–
13.23)
3.431 (3.289–3.572) 0.045 (0.044–0.047)
Liaoning 1360 7366 4695 539 338 14,298 3.59 (3.43–
3.75)
11.79 (11.31–
12.26)
7.60 (7.30–7.91) 0.86 (0.83–
0.90)
0.54 (0.47–
0.56)
24.38 (23.38–
25.38)
5.577 (5.348–5.804) 0.054 (0.052–0.056)
Jilin 968 4094 2884 300 200 8446 2.55 (2.43–
2.66)
6.55 (6.29–
6.81)
4.68 (4.49–4.87) 0.48 (0.46–
0.50)
0.32 (0.28–
0.33)
14.58 (13.98–
15.18)
4.442 (4.259–4.624) 0.068 (0.065–0.070)
Heilongjiang 1249 5627 4030 348 279 11,533 3.27 (3.12–
3.42)
9.00 (8.64–
9.37)
6.54 (6.28–6.81) 0.56 (0.53–
0.58)
0.45 (0.39–
0.46)
19.82 (19.01–
20.63)
5.779 (5.541–6.015) 0.083 (0.080–0.086)
Shanghai 809 3778 2441 324 192 7544 2.13 (2.03–
2.22)
6.04 (5.80–
6.29)
3.94 (3.78–4.10) 0.52 (0.50–
0.54)
0.31 (0.27–
0.32)
12.94 (12.41–
13.47)
3.106 (2.979–3.233) 0.036 (0.035–0.038)
Jiangsu 3471 13,510 7631 1379 551 26,542 9.08 (8.67–
9.48)
21.62 (20.75–
22.49)
12.42 (11.92–
12.92)
2.21 (2.12–
2.30)
0.88 (0.77–
0.92)
46.20 (44.29–
48.10)
5.066 (4.857–5.274) 0.047 (0.045–0.049)
Zhejiang 2211 8313 5422 1095 427 17,468 5.80 (5.54–
6.06)
13.30 (12.76–
13.84)
8.80 (8.44–9.15) 1.75 (1.68–
1.82)
0.68 (0.60–
0.71)
30.34 (29.09–
31.58)
4.647 (4.455–4.837) 0.049 (0.047–0.051)
Anhui 3303 9099 5665 876 354 19,297 8.60 (8.21–
8.98)
14.56 (13.97–
15.14)
9.24 (8.86–9.61) 1.40 (1.35–
1.46)
0.57 (0.49–
0.59)
34.36 (32.93–
35.78)
4.981 (4.774–5.187) 0.109 (0.104–0.113)
Fujian 2057 4543 3593 709 262 11,164 5.35 (5.10–
5.59)
7.27 (6.98–
7.56)
5.85 (5.62–6.09) 1.13 (1.09–
1.18)
0.42 (0.37–
0.44)
20.02 (19.19–
20.85)
4.499 (4.311–4.685) 0.055 (0.053–0.058)
Jiangxi 3128 5645 4037 778 270 13,857 8.19 (7.82–
8.56)
9.03 (8.67–
9.40)
6.61 (6.34–6.88) 1.24 (1.19–
1.29)
0.43 (0.38–
0.45)
25.51 (24.44–
26.57)
4.716 (4.518–4.912) 0.107 (0.103–0.112)
Shandong 5195 15,369 9398 1271 819 32,053 13.51 (12.89–
14.11)
24.59 (23.60–
25.58)
15.29 (14.67–
15.91)
2.03 (1.95–
2.12)
1.31 (1.14–
1.36)
56.73 (54.38–
59.08)
5.979 (5.730–6.225) 0.062 (0.060–0.065)
Henan 6662 12,873 8467 1885 716 30,604 17.42 (16.63–
18.19)
20.60 (19.77–
21.43)
13.84 (13.28–
14.40)
3.02 (2.89–
3.14)
1.15 (1.00–
1.19)
56.01 (53.67–
58.34)
6.009 (5.758–6.259) 0.105 (0.101–0.109)
Hubei 2841 8751 5674 902 411 18,579 7.38 (7.04–
7.71)
14.00 (13.44–
14.57)
9.24 (8.87–9.61) 1.44 (1.39–
1.50)
0.66 (0.57–
0.68)
32.72 (31.37–
34.07)
5.350 (5.128–5.570) 0.080 (0.077–0.083)
Hunan 3991 10,439 6261 1062 442 22,196 10.37 (9.90–
10.83)
16.70 (16.03–
17.38)
10.22 (9.81–
10.63)
1.70 (1.63–
1.77)
0.71 (0.62–
0.74)
39.70 (38.04–
41.34)
6.084 (5.831–6.336) 0.098 (0.094–0.102)
Guangdong 5723 10,871 9668 2248 708 29,219 14.76 (14.09–
15.42)
17.39 (16.69–
18.09)
15.67 (15.04–
16.30)
3.60 (3.45–
3.74)
1.13 (0.99–
1.18)
52.56 (50.36–
54.74)
4.740 (4.542–4.937) 0.051 (0.049–0.053)
Guangxi 3574 6461 4145 1174 335 15,688 9.24 (8.81–
9.65)
10.34 (9.92–
10.75)
6.78 (6.51–7.05) 1.88 (1.80–
1.95)
0.54 (0.47–
0.56)
28.77 (27.56–
29.97)
5.372 (5.146–5.596) 0.120 (0.115–0.126)
Hainan 580 1065 811 183 63 2702 1.52 (1.45–
1.59)
1.70 (1.64–
1.77)
1.32 (1.27–1.38) 0.29 (0.28–
0.30)
0.10 (0.09–
0.11)
4.94 (4.73–
5.14)
3.842 (3.681–4.001) 0.095 (0.091–0.098)
Chongqing 1465 5379 2825 571 198 10,438 3.81 (3.63–
3.97)
8.61 (8.26–
8.95)
4.59 (4.41–4.78) 0.91 (0.88–
0.95)
0.32 (0.28–
0.33)
18.24 (17.48–
18.99)
4.842 (4.642–5.042) 0.087 (0.083–0.090)
Sichuan 3808 14,016 7632 1415 596 27,467 9.93 (9.47–
10.37)
22.43 (21.52–
23.33)
12.43 (11.93–
12.93)
2.26 (2.17–
2.36)
0.95 (0.83–
0.99)
48.00 (46.02–
49.98)
5.293 (5.074–5.511) 0.110 (0.106–0.115)
Guizhou 2314 4796 3045 483 222 10,860 5.98 (5.70–
6.24)
7.67 (7.37–
7.98)
4.97 (4.77–5.17) 0.77 (0.74–
0.80)
0.35 (0.31–
0.37)
19.75 (18.92–
20.57)
4.277 (4.098–4.455) 0.149 (0.142–0.155)
Yunnan 2596 5506 4295 786 266 13,449 6.81 (6.50–
7.11)
8.81 (8.45–
9.16)
7.00 (6.72–7.28) 1.26 (1.21–
1.31)
0.42 (0.37–
0.44)
24.30 (23.28–
25.30)
4.542 (4.353–4.730) 0.125 (0.120–0.130)
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J. Yang et al. / Vaccine 34 (2016) 5724–5735 5733capacity meets demand in a future pandemic [12]. This low cover-
age precluded any meaningful control of seasonal disease burden
and negatively impacted China’s preparedness for an influenza
pandemic. To improve seasonal influenza vaccine coverage, reduce
the disease burden and prepare for the next pandemic in China,
will require political commitment and sustained public health
investment.
We evaluated the budget needed to fund a potential national
program on influenza vaccination. This money (US$ 757 million,
95%CI 726–789) is 4.777‰ (4.579–4.975) of total government
health expenditures and 0080‰ (0.077–0.083) of GDP in 2015.
To quantify and compare such a program with other health-care
decisions, it would be helpful to implement a cost-effectiveness
analysis that incorporates the annual outlay due to vaccine costs
(calculated in this study) as well as (1) the downstream cost sav-
ings through averted medical visits and deaths, and (2) the quality
of life gained through decreased influenza-associated morbidity
and mortality.
This was the first study to comprehensively collect influenza
vaccine reimbursement information across China. Our online sur-
vey was conducted at the provincial-level CDCs because of the dif-
ficulty of contacting all district-level CDCs, a few of whom could
not provide complete information for their entire province.
Although we supplemented the survey data with information
obtained from official websites, there was some missing informa-
tion. In spite of this limitation, we believe this study provides a
detailed picture of the current reimbursement policy landscape.
Our budget analysis may underestimate total costs as we did not
assess the need for additional investments in the vaccine cold
chain that could be required to support a national influenza vacci-
nation program.
5. Conclusions
This was the first detailed analysis of the landscape of influenza
vaccine reimbursement policies across China. Although an increas-
ing number of regional governments have begun to pay, partially
or fully, for influenza vaccination for selected groups, this patch-
work of small-scale sub-national policies have failed to increase
national uptake of the vaccine, which remains low. A national, free
seasonal influenza vaccination program for priority populations
would be costly; a cost-effectiveness analysis is needed to identify
the most efficient way to improve vaccination coverage rates and
better control influenza disease burden in China.
Contributors
JY, LF and HY designed the analysis; JY, LF, MP, YZ and XL col-
lected data; JY, KA conducted the data analysis and drafted the
manuscript; JY, KA, LF, BC and HY contributed to the interpretation
of the results and to the revision of the manuscript.
Conflict of interest
None.
Acknowledgements
This study was funded by grants from the National Science
Fund for Distinguished Young Scholars (No. 81525023) (http://
www.nsfc.gov.cn/publish/portal1/) (HY) the US National Institutes
of Health (Comprehensive International Program for Research on
AIDS grant U19 AI51915) (http://nih.gov/) (HY). The funding bodies
had no role in study design, data collection and analysis, prepara-
tion of the manuscript, or the decision to publish.
5734 J. Yang et al. / Vaccine 34 (2016) 5724–5735The authors thank staffs at the 31 provincial Centers for Disease
Control and Prevention to provide information on local reimburse-
ment policies of influenza vaccination. We sincerely thank Dr.
Mark Simmerman from Sanofi Pasteur for the valuable comments
to the revision of the manuscript.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.10.
013.
References
[1] World Health Organization. Fact sheet on seasonal influenza. Available from:
<http://www.who.int/mediacentre/factsheets/fs211/en/>. [accessed 2015
April 28].
[2] World Health Organiztion. Vaccines against influenza WHO position paper-
November 2012. Wkly Epidemiol Rec 2012;87(47):461–76 [PMID: 23210147].
[3] World Health Organiztion. Global action plan for influenza vaccines (GAP):
questionnaire on progress made and remaining gaps. Available from: <https://
www.surveymonkey.com/r/WHO-GAP>. [accessed 2015 December 28].
[4] World Health Organizaiton. Seasonal influenza vaccine policy and utilization:
a global perspective. Available from: <http://www.who.int/
influenza_vaccines_plan/resources/hombach.pdf>. [accessed 2015 December
21].
[5] Gupta V, Fs Dawood, Muangchana C, et al. Influenza vaccination guidelines and
vaccine sales in southeast Asia: 2008–2011. PLoS ONE 2012;7(12):e52842. doi:
http://dx.doi.org/10.1371/journal.pone.0052842 [PMID: 23285200].
[6] Luna EJ, Gattás VL. Effectiveness of the Brazilian influenza vaccination policy, a
systematic review. Rev Inst Med Trop Sao Paulo 2010;52(4):175–81 [PMID:
21748222].
[7] Members of theWestern Pacific Region Global Influenza Surveillance Response
System Dwyer D, Barr I, Hurt A, Kelso A, Reading P, et al. Seasonal influenza
vaccine policies, recommendations and use in the World Health Organization’s
Western Pacific Region. Western Pac Surveill Response J 2013;4(3):51–9. doi:
http://dx.doi.org/10.5365/WPSAR.2013.4.1.009 [PMID: 24319615].
[8] Miller E. Report from the SAGE Working Group on Influenza Vaccines and
Immunizations. In: SAGE meeting November 10, 2010. Available at <http://
www.who.int/immunization/sage/nov2010sageinfluenzawgupdatemiller.pdf>
[accessed 2014 December 20].
[9] Yu H, Feng L, Viboud CG, et al. Regional variation in mortality impact of the
2009 A(H1N1) influenza pandemic in China. Influenza Other Respir Viruses
2013;7(6):1350–60. doi: http://dx.doi.org/10.1111/irv.12121 [PMID:
23668477].
[10] Feng L, Mounts AW, Feng Y, et al. Seasonal influenza vaccine supply and target
vaccinated population in China, 2004–2009. Vaccine 2010;28:6778–82. doi:
http://dx.doi.org/10.1016/j.vaccine.2010.07.064 [PMID: 20688038].
[11] Zhou L, Su Q, Xu Z, et al. Seasonal influenza vaccination coverage rate of target
groups in selected cities and provinces in China by season (2009/10 to 2011/
12). PLoS ONE 2013;8(9):e73724. doi: http://dx.doi.org/10.1371/journal.
pone.0073724.
[12] Fifty-sixth World Health Assembly resolution WHA56.19. Prevention and
control of influenza pandemics and annual epidemics. 28 May 2003. Available
from: <http://www.who.int/immunization/sage/1_WHA56_19_Prevention_
and_control_of_influenza_pandemics.pdf>. [accessed 2015 September 25].
[13] Palache A. Seasonal influenza vaccine provision in 157 countries (2004–2009)
and the potential influence of national public health policies. Vaccine 2011;29
(51):9459–66. doi: http://dx.doi.org/10.1016/j.vaccine.2011.10.030 [PMID:
22024174].
[14] Fedson DS, Hirota Y, Shin HK, et al. Influenza vaccination in 22 developed
countries: an update to 1995. Vaccine 1997;15(14):1506–11 [PMID:
9330460].
[15] Chinadaily: WHO says list of free vaccines should be expanded. Available:
<http://africa.chinadaily.com.cn/china/2016-03/30/content_24171305.htm>.
[accessed on 2016 May 17].
[16] National Bureau of Statistics of China. China Statistical Yearbook 2014.
Chinese. Available: <http://www.stats.gov.cn/tjsj/ndsj/2014/indexch.htm>.
[accessed 2014 April 11].
[17] Parmar D, Baruwa Em, Zuber P, Kone S. Impact of wastage on single and multi-
dose vaccine vials: Implications for introducing pneumococcal vaccines in
developing countries. Hum Vaccine 2010;6(3) [pii: 10397].
[18] Setia S, Mainzer H, Washington ML, Coil G, Snyder R, Weniger BG. Frequency
and causes of vaccine wastage. Vaccine 2002;20(7–8):1148–56 [PMID:
11803076].
[19] Kelly H, Cowling BJ. Evidence and policy for influenza control. Euro Surveill
2014;19(27):2–4 [PMID: 25033050].
[20] Chinese Center for Disease Control and Prevention. Techinical guidelines for
the application of seasonal influenza vaccine in China (2014–2015). Chinese.
Available from: <http://www.chinacdc.cn/jkzt/crb/lxxgm/ymjz/201411/
t20141118_106496.htm>. [accessed 2015 April 12].[21] National Health and Family Planning Commission of China. China Health
Statistical Yearbook. Available from: <http://www.moh.gov.cn/zwgkzt/tjnj/
list.shtml>. [accessed 2015 April 12].
[22] Wang YP, Liang J, Zhu J, Zhou GX, Miao L, Dai L. Ananlysis of the perinatal death
and related male/female ratio of hospital delivery in China during 1988–1992.
J Pract Obstet Gynecol 2001;17(3):173–4.
[23] Liu B, Gao ES. Risk factors for spontaneous abortion of Chinese married women
at reproductive age. Chinese. China Public Health 2002;18(7):890–2.
[24] Zhong NS, Wang C, Yao WZ, et al. Prevalence of chronic obstructive pulmonary
disease in China: a large, population-based survey. Am J Respir Crit Care Med
2007;176:753–60. doi: http://dx.doi.org/10.1164/rccm.200612-1749O [PMID:
17575095].
[25] Hong XQ, Dai AG, Kong CC, et al. Prevalence of chronic obstructive pulmonary
disease in Hunan province. Chinese. Chin J Gerontol 2012;32:796–7.
[26] The National Cooperative Group on Childhood Asthma, Institute of
Environmental Health and Related Product Safety, Chinese Center for
Disease Control and Prevention. Third national survey of childhood asthma
in urban areas of China. Chinese. Chin J Pediatr 2013; 51(10): 729–35. [PMID:
24406223].
[27] WangWY, Lin JT, Su N, et al. Survey on the prevalence rate of bronchial asthma
in Beijing area among the residents aged over 14 years from 2010 to 2011.
Chinese. Natl Med J China 2013;93(18):1383–7 [PMID: 24025502].
[28] Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY. Prevalence of cardiovascular
disease risk factor in the Chinese population: the 2007-2008: China National
Diabetes and Metabolic Disorders Study. Eur Heart J 2012;33:213–20. doi:
http://dx.doi.org/10.1093/eurheartj/ehr205 [PMID: 21719451].
[29] Gu DF, Huang GY, He J, et al. Investigation of prevalence and distributing
feature of chronic heart failure in Chinese adult population. Chinese. Chin J
Cardiol 2003;31(1):3–6.
[30] Chen QH, Liu FY, Wang XQ, et al. A cross-sectional study of congenital heart
disease among children aged from 4 to 18 years at different altitudes in
Qinghai province, China. Chinese. Chin J Epidemiol 2009;30(12):1248–51
[PMID: 20193307].
[31] Liu HY, Liu YF, Wang LX, et al. Prevalence of primary biliary cirrhosis in adults
referring hospital for annual health check-up in Southern China. BMC
Gastroenterol 2010;10:100. doi: http://dx.doi.org/10.1186/1471-230X-10-
100 [PMID: 20815889].
[32] Li YM, Chen WX, Yu CH, et al. An epidemiological survey of alcoholic liver
disease in Zhejiang province. Chinese. Chin J Hepatol 2003;11(11):647–9
[PMID: 14636435].
[33] Yang SG, Wang B, Chen P, et al. Effectiveness of HBV vaccination in infants and
prediction of HBV prevalence trend under new vaccination plan: findings of a
large-scale investigation. PLoS ONE 2012;7(10):e47808. doi: http://dx.doi.org/
10.1371/journal.pone.0047808 [PMID: 23094094].
[34] Zhang LX, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China:
a cross-sectional survey. Lancet 2012;379:815–22. doi: http://dx.doi.org/
10.1016/S0140-6736(12)60033-6 [PMID: 22386035].
[35] Center for Health Statistics and Information. Ministry of Health: An analysis
report of national health services survey in China. 1st ed. Beijing: Peking Union
Medical College Press; 2008.
[36] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults.
JAMA 2013;310(9):948–59. doi: http://dx.doi.org/10.1001/jama.2013.168118
[PMID: 24002281].
[37] Fu P, Man Q, Zhang J, Wang C. Epidemiological study on diabetes mellitus in
Chinese children and adolescents at the age of 5 to 17 years. Chinese. J Hyg Res
2007;36(6):722–4 [PMID: 18303636].
[38] Li L, Duanmu HJ. The epidemic of childhood tuberculosis in China. Chinese.
Natl Med J China 2004;84(20):1678–80 [PMID: 15569423].
[39] Wang Y. The report of the fifth national tuberculosis epidemiological survey in
2010. Beijing: Military Medical Sciences Press; 2011. p. 17–9.
[40] Wu J, Dong ZY, Ding LX, Liu HL. Influenza vaccination practice in Beijing during
1999-2004. Chinese. J Pub Health Pre Med 2005;16(4):19–21.
[41] Wu S, Yang P, Li H, Ma C, Zhang Y, Wang Q. Influenza vaccination coverage
rates among adults before and after the 2009 influenza pandemic and the
reasons for non-vaccination in Beijing, China: a cross-sectional study. BMC
Public Health 2013;13:636. doi: http://dx.doi.org/10.1186/1471-2458-13-636
[PMID: 23835253].
[42] Owusu JT, Prapasiri P, Ditsungnoen D, et al. Seasonal influenza vaccine
coverage among high-risk populations in Thailand, 2010-2012. Vaccine
2015;33(5):742–7. doi: http://dx.doi.org/10.1016/j.vaccine.2014.10.029
[PMID: 25454853].
[43] Yao YP, Wu JY, Gu LH, Yu FY, Wu WX. Policy analysis on management of
category II vaccines price. Chinese. Zhejiang Prev Med 2012;24(1):83–5.
[44] Yin Z, Beeler Asay GR, Zhang L, et al. An economic evaluation of the use of
Japanese encephalitis vaccine in the expanded program of immunization of
Guizhou province, China. Vaccine 2012;30(37):5569–77. doi: http://dx.doi.
org/10.1016/j.vaccine.2012.05.068 [PMID: 22698453].
[45] National Bureau of Statistics of China. Consumer Price Index Available:
<http://data.stats.gov.cn/english/easyquery.htm?cn=C01>. [accessed 2015
September 2].
[46] The World Bank. Official exchange rate. Available from:
<http://data.worldbank.org/indicator/PA.NUS.FCRF>. [accessed 2015
September 2].
[47] Parry J. Crackdown on illegal vaccine sales in China leads to 37 arrests. BMJ
2016;352:i1750. doi: http://dx.doi.org/10.1136/bmj.i1750 [PMID: 27013557].
J. Yang et al. / Vaccine 34 (2016) 5724–5735 5735[48] Decision of the State Council on amending Regulations on Management of
Vaccine Circulation and Inoculation (Order No. 668 of the State Council of the
People’s Republic of China). Available: <http://www.gov.cn/zhengce/content/
2016-04/25/content_5067597.htm>. [accessed 2016 May 17].
[49] Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M. Seasonal influenza
vaccine dose distribution in 195 countries (2004–2013): Little progress in
estimated global vaccination coverage. Vaccine 2015;33(42):5598–605. doi:
http://dx.doi.org/10.1016/j.vaccine.2015.08.082 [PMID: 26368399].
[50] Yeung MP, Ng SK, Tong ET, Chan SS, Coker R. Factors associated with uptake of
influenza vaccine in people aged 50 to 64 years in Hong Kong: a case-control
study. BMC Public Health 2015;15:617. doi: http://dx.doi.org/10.1186/
s12889-015-1990-0 [PMID: 26148496].
[51] Mo PK, Lau JT. Influenza vaccination uptake and associated factors among
elderly population in Hong Kong: the application of the Health Belief Model.
Health Educ Res 2015;30(5):706–18. doi: http://dx.doi.org/10.1093/
her/cyv038 [PMID: 26336905].[52] Shono A, Kondo M. Factors associated with seasonal influenza vaccine uptake
among children in Japan. BMC Infect Dis 2015;15:72. doi: http://dx.doi.org/
10.1186/s12879-015-0821-3 [PMID: 25886607].
[53] Bulletin of the national economic and social development of Min County in
2013 (in Chinese). Available from: <http://www.mxzwfw.gov.cn/index.php/
cms/item-view-id-1169.shtml>. [accessed 2015 October 12].
[54] Li C, Yu X, Butler JR, Yiengprugsawan V, Yu M. Moving towards universal
health insurance in China: performance, issues and lessons from Thailand. Soc
Sci Med 2011;73(3):359–66. doi: http://dx.doi.org/10.1016/
j.socscimed.2011.06.002 [PMID: 21733610].
[55] Palache A, Oriol-Mathieu V, Abelin A, Music T. Seasonal influenza vaccine dose
distribution in 157 countries (2004–2011). Vaccine 2014;32(48):6369–76.
doi: http://dx.doi.org/10.1016/j.vaccine.2014.07.012 [PMID: 25442403].
[56] Centers for Disease Control and Prevention. Flu Vaccination Coverage, United
States, 2014-15 Influenza Season. Available from: <http://www.cdc.gov/flu/
fluvaxview/coverage-1415estimates.htm>. [accessed 2015 September 24].
